emodin has been researched along with Obesity in 13 studies
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Emodin has a protective effect on asthma." | 8.12 | Emodin inhibits NF-κB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin. ( Cai, W; He, X; Hu, J; Miao, J, 2022) |
| "Emodin is a natural anthraquinone derivative that exhibits variety of pharmacologic effects including lowering lipids and regulating glucose utilization." | 5.62 | Emodin Improves Glucose and Lipid Metabolism Disorders in Obese Mice ( Cheng, L; Dong, S; He, R; Huang, Z; Ning, Y; Shang, F; Sun, J; Zhang, S, 2021) |
| "Emodin has been shown to exert strong anti-inflammatory property via acting on macrophages in a range of disease models." | 5.62 | Emodin inhibits lipid accumulation and inflammation in adipose tissue of high-fat diet-fed mice by inducing M2 polarization of adipose tissue macrophages. ( Peng, J; Wang, F; Wang, X; Xu, X; Yu, F; Yu, N; Zhang, L; Zhao, Y; Zhou, J, 2021) |
| "After 8-week treatment, body weight, wet weight of visceral fat and the percentage of body fat (PBF) were measured." | 5.40 | Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats. ( Chang, X; Chao, J; Han, S; Huang, Q; Lin, H; Lu, K; Qu, S; Shen, C; Song, X; Tan, M; Wang, C; Xie, S; Xu, L; Yuan, Q; Zhang, J, 2014) |
| "Emodin is an active herbal component traditionally used in China for treating a variety of diseases." | 5.38 | Emodin protects against high-fat diet-induced obesity via regulation of AMP-activated protein kinase pathways in white adipose tissue. ( Chang, CJ; Liou, SS; Liu, IM; Lu, HJ; Tzeng, TF, 2012) |
| "Emodin has a protective effect on asthma." | 4.12 | Emodin inhibits NF-κB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin. ( Cai, W; He, X; Hu, J; Miao, J, 2022) |
| " The ability of emodin to inhibit prednisone- or dexamethasone-induced insulin resistance was investigated in C57BL/6J mice and its effect on metabolic abnormalities was observed in DIO mice." | 3.76 | Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. ( Chen, JH; Dou, W; Feng, Y; Huang, SL; Leng, Y; Shen, JH; Shen, Y; Zhang, S, 2010) |
| "Emodin is a natural anthraquinone derivative that exhibits variety of pharmacologic effects including lowering lipids and regulating glucose utilization." | 1.62 | Emodin Improves Glucose and Lipid Metabolism Disorders in Obese Mice ( Cheng, L; Dong, S; He, R; Huang, Z; Ning, Y; Shang, F; Sun, J; Zhang, S, 2021) |
| "Emodin has been shown to exert strong anti-inflammatory property via acting on macrophages in a range of disease models." | 1.62 | Emodin inhibits lipid accumulation and inflammation in adipose tissue of high-fat diet-fed mice by inducing M2 polarization of adipose tissue macrophages. ( Peng, J; Wang, F; Wang, X; Xu, X; Yu, F; Yu, N; Zhang, L; Zhao, Y; Zhou, J, 2021) |
| "Emodin was admixed to high fat-food of obese mice at two doses (2 and 5g/kg; daily emodin uptake 103 and 229mg/kg)." | 1.46 | Emodin, a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents. ( Abu Eid, S; Adams, M; Fürnsinn, C; Hackl, MT; Kaplanian, M; Luger, A; Riedl, R; Scherer, T; Torres-Gómez, H, 2017) |
| "Currently, obesity has become a worldwide epidemic associated with Type 2 diabetes, dyslipidemia, cardiovascular disease and chronic metabolic diseases." | 1.43 | Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway. ( Ding, L; Li, J; Qi, M; Song, B; Tang, X; Wang, Z; Xiao, X; Yang, L; Yang, Q, 2016) |
| "After 8-week treatment, body weight, wet weight of visceral fat and the percentage of body fat (PBF) were measured." | 1.40 | Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats. ( Chang, X; Chao, J; Han, S; Huang, Q; Lin, H; Lu, K; Qu, S; Shen, C; Song, X; Tan, M; Wang, C; Xie, S; Xu, L; Yuan, Q; Zhang, J, 2014) |
| "Emodin is an active herbal component traditionally used in China for treating a variety of diseases." | 1.38 | Emodin protects against high-fat diet-induced obesity via regulation of AMP-activated protein kinase pathways in white adipose tissue. ( Chang, CJ; Liou, SS; Liu, IM; Lu, HJ; Tzeng, TF, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Miao, J | 1 |
| He, X | 1 |
| Hu, J | 1 |
| Cai, W | 1 |
| Otoo, A | 1 |
| Czika, A | 1 |
| Lamptey, J | 1 |
| Yang, JP | 1 |
| Feng, Q | 1 |
| Wang, MJ | 1 |
| Wang, YX | 1 |
| Ding, YB | 1 |
| Cheng, L | 1 |
| Zhang, S | 2 |
| Shang, F | 1 |
| Ning, Y | 1 |
| Huang, Z | 1 |
| He, R | 1 |
| Sun, J | 1 |
| Dong, S | 1 |
| Yu, F | 1 |
| Yu, N | 1 |
| Peng, J | 1 |
| Zhao, Y | 1 |
| Zhang, L | 1 |
| Wang, X | 1 |
| Xu, X | 1 |
| Zhou, J | 1 |
| Wang, F | 2 |
| Washington, K | 1 |
| Wason, J | 1 |
| Thein, MS | 1 |
| Lavery, LA | 1 |
| Hamblin, MR | 1 |
| Gordon, IL | 1 |
| Nong, F | 1 |
| Zhao, Z | 1 |
| Luo, X | 1 |
| Liu, C | 1 |
| Li, H | 1 |
| Liu, Q | 1 |
| Wen, B | 1 |
| Zhou, L | 1 |
| Buddeberg, BS | 1 |
| Sharma, R | 1 |
| O'Driscoll, JM | 1 |
| Kaelin Agten, A | 1 |
| Khalil, A | 1 |
| Thilaganathan, B | 1 |
| Wakabayashi, H | 1 |
| Osawa, M | 1 |
| Koga, S | 1 |
| Li, K | 1 |
| Sakaue, H | 1 |
| Sengoku, Y | 1 |
| Takagi, H | 1 |
| Kim, SW | 1 |
| Son, Y | 2 |
| Choi, K | 1 |
| Kim, SI | 1 |
| Park, J | 1 |
| Lee, JH | 1 |
| Jang, JH | 1 |
| Brailsford, AD | 1 |
| Majidin, WNM | 1 |
| Wojek, N | 1 |
| Cowan, DA | 1 |
| Walker, C | 1 |
| Kim, JH | 1 |
| Phi, JH | 1 |
| Lee, JY | 1 |
| Kim, KH | 1 |
| Park, SH | 1 |
| Choi, YH | 1 |
| Cho, BK | 1 |
| Kim, SK | 1 |
| Kim, HJ | 1 |
| Pei, M | 1 |
| Ko, JS | 1 |
| Ma, MH | 1 |
| Park, GE | 1 |
| Baek, J | 1 |
| Yang, H | 1 |
| Cho, MJ | 1 |
| Choi, DH | 1 |
| Reyes-Garcia, JG | 1 |
| Rodríguez-Flores, M | 1 |
| Kaufer-Horwitz, M | 1 |
| García-García, E | 1 |
| Lu, K | 1 |
| Xie, S | 1 |
| Han, S | 1 |
| Zhang, J | 1 |
| Chang, X | 1 |
| Chao, J | 1 |
| Huang, Q | 1 |
| Yuan, Q | 1 |
| Lin, H | 1 |
| Xu, L | 1 |
| Shen, C | 1 |
| Tan, M | 1 |
| Qu, S | 1 |
| Wang, C | 1 |
| Song, X | 1 |
| Li, J | 1 |
| Ding, L | 1 |
| Song, B | 1 |
| Xiao, X | 1 |
| Qi, M | 1 |
| Yang, Q | 2 |
| Tang, X | 1 |
| Wang, Z | 1 |
| Yang, L | 1 |
| Ma, F | 1 |
| Hu, L | 1 |
| Yu, M | 1 |
| Abu Eid, S | 1 |
| Adams, M | 1 |
| Scherer, T | 1 |
| Torres-Gómez, H | 1 |
| Hackl, MT | 1 |
| Kaplanian, M | 1 |
| Riedl, R | 1 |
| Luger, A | 1 |
| Fürnsinn, C | 1 |
| Feng, Y | 1 |
| Huang, SL | 1 |
| Dou, W | 1 |
| Chen, JH | 1 |
| Shen, Y | 1 |
| Shen, JH | 1 |
| Leng, Y | 1 |
| Tzeng, TF | 1 |
| Lu, HJ | 1 |
| Liou, SS | 1 |
| Chang, CJ | 1 |
| Liu, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy of Chinese Herbal Medicine in Patients With Obesity: a Retrospective Study[NCT04481464] | 500 participants (Anticipated) | Observational | 2020-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for emodin and Obesity
| Article | Year |
|---|---|
Emodin inhibits NF-κB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin.
Topics: Animals; Asthma; Cytokines; Disease Models, Animal; Emodin; Male; NF-kappa B; Nicotinamide Phosphori | 2022 |
Emodin improves glucose metabolism and ovarian function in PCOS mice via the HMGB1/TLR4/NF-κB molecular pathway.
Topics: Animals; Emodin; Female; Glucose; HMGB1 Protein; Humans; Mice; NF-kappa B; Obesity; Polycystic Ovary | 2023 |
Emodin Improves Glucose and Lipid Metabolism Disorders in Obese Mice
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Body Weight; Diet, High-Fat; Emodin; Lipid Me | 2021 |
Emodin inhibits lipid accumulation and inflammation in adipose tissue of high-fat diet-fed mice by inducing M2 polarization of adipose tissue macrophages.
Topics: 3T3-L1 Cells; Adipogenesis; Adipose Tissue; Animals; Cell Line; Diet, High-Fat; Emodin; Inflammation | 2021 |
Topics: Adult; Anabolic Agents; Androgens; Animals; Anthraquinones; Birth Weight; Body Mass Index; Carbon Is | 2018 |
Safety of drug combinations based on psychoactive agents in the treatment of obesity (A reply by the authors).
Topics: Atropine; Diazepam; Drug Combinations; Emodin; Humans; Obesity; Phenylpropanolamine; Psychotropic Dr | 2019 |
Safety of drug combinations based on psychoactive agents in the treatment of obesity.
Topics: Atropine; Diazepam; Drug Combinations; Emodin; Humans; Obesity; Phenylpropanolamine; Psychotropic Dr | 2019 |
Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Body Weight; Cell Cycle Proteins; Emodin; Lipase; Lipo | 2014 |
Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway.
Topics: Adipose Tissue; Animals; Cell Line; Diet, High-Fat; Down-Regulation; Emodin; Glucose; Humans; Insuli | 2016 |
Emodin Decreases Hepatic Hypoxia-Inducible Factor-1[Formula: see text] by Inhibiting its Biosynthesis.
Topics: Animals; Emodin; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1; Liver; Male; Mice; Mice, Inbred C | 2016 |
Emodin, a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Eating; Emodi | 2017 |
Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenal Cortex Hormones; Animals; Cell Line; Dexamethas | 2010 |
Emodin protects against high-fat diet-induced obesity via regulation of AMP-activated protein kinase pathways in white adipose tissue.
Topics: 3T3-L1 Cells; Adipocytes, White; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Anti | 2012 |